anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The recommended starting dose is 1 mg. Dosing can be raised to 2 mg or 3 mg if clinically indicated. In some patients, the higher morning blood levels of eszopiclone tablets following use of the 2 mg or 3 mg dose increase the risk of next day impairment of driving and other activities that require full alertness [see Warnings and Precautions (Error! Hyperlink reference not valid.)]. The total dose of eszopiclone tablets should not exceed 3 mg, once daily immediately before bedtime [see Warnings and Precautions (Error! Hyperlink reference not valid.)].
BACKGROUND: Hepatic fibrosis, a common pathological process that occurs in end-stage liver diseases, is a serious public health problem and lacks effective therapy. Notoginsenoside R1 (NR1) is a small molecule derived from the traditional Chinese medicine Sanqi, exhibiting great potential in treating diverse metabolie disorders. Here we aimed to enquired the role of NR1 in liver fibrosis and its underlying mechanism in hepatoprotective effects.
METHODS: We investigated the anti-fibrosis effect of NR1 using CCl4-induced mouse mode of liver fibrosis as well as TGF-β1-activated JS-1, LX-2 cells and primary hepatic stellate cell. Cell samples treated by NR1 were collected for transcriptomic profiling analysis. PPAR-γ mediated TGF-β1/Smads signaling was examined using PPAR-γ selective inhibitors and agonists intervention, immunofluorescence staining and western blot analysis. Additionally, we designed and studied the binding of NR1 to PPAR-γ using molecular docking.
RESULTS: NR1 obviously attenuated liver histological damage, reduced serum ALT, AST levels, and decreased liver fibrogenesis markers in mouse mode. Mechanistically, NR1 elevated PPAR-γ and decreased TGF-β1, p-Smad2/3 expression. The TGF-β1/Smads signaling pathway and fibrotic phenotype were altered in JS-1 cells after using PPAR-γ selective inhibitors and agonists respectively, confirming PPAR-γ played a pivotal protection role inNR1 treating liver fibrosis. Further molecular docking indicated NR1 had a strong binding tendency to PPAR-γ with minimum free energy.
CONCLUSIONS: NR1 attenuates hepatic stellate cell activation and hepatic fibrosis by elevating PPAR-γ to inhibit TGF-β1/Smads signalling. NR1 may be a potential candidate compound for reliving liver fibrosis.
Participants received 300 mg posaconazole (POS) intravenous (IV) twice per day (BID) on Day 1, and then received 300 mg POS IV plus placebo IV once per day (QD) starting on Day 2 until clinically stable when participants transitioned to oral POS tablets plus oral placebo tablets QD for up to 12 weeks of treatment. Most participants were expected to initiate treatment with IV therapy and transition to oral therapy as clinically indicated, with some participants initiating treatment with oral therapy, per clinical judgment.
PURPOSE:To obtain a cosmetic, containing an extract separated from leaves of Nelumbo nucifera Gaertn. as an active ingredient, having beautifying and whitening action and preventive effects on skin roughening, good in safety and readily securing raw materials. CONSTITUTION:Dried leaves of Nelumbo nucifera Gaertn. are extracted by using a water-soluble organic solvent (e.g. ethanol) and, as necessary, adding water while being stirred. The resultant extract solution as an active ingredient is included in a cosmetic. The amount thereof blended is 0.01-5wt.%, preferably 0.05-2wt.% expressed in terms of a dried extract. In addition to the extract solution from the leaves of the Nelumbo nucifera Gaertn., oils, surfactants, medicines, etc., normally used in cosmetics are suitably blended to prepare the objective cosmetic. The leaves of the Nelumbo nucifera Gaertn. have diuretic, antipyretic, antidiarrheic, antipyreticotic actions, etc., and further inhibitory action on Salmonella typhi and Bacillus dysteneriae and are used as a herb medicine, but not as the cosmetic at all.
Thousands of individuals are affected by deep vein thrombosis (DVT) every year. Medical treatment is aimed at preventing extension and recurrence of the blood clot (DVT) through the use of anticoagulation medication. Compression stockings may be added for reduction of pain and swelling, but this therapy remains controversial amongst physicians. To date, there is limited manual therapies available for individuals affected with DVT. Regular medical treatment, anticoagulation medication, along with osteopathic treatment may offer these individuals improved control of the symptoms associated with DVT. In the long term osteopathic treatment may provide an increase in the quality of life (QOL) and improve the signs and symptoms associated with the post-thrombotic syndrome (PTS), which can be burdensome for both the individual and the health care system. Offering an effective add on treatment could provide individuals and the medical system with an additional means of treatment for the symptoms of DVT and also for the prevention of development of PTS.
Participants will receive a 60-minute session of motivational interviewing via videoconference or telephone (at participant discretion) in their home from a trained nurse. The nurse will apply motivational interviewing techniques to explore the patient's thoughts about making a behavior change to attain adequate physical activity (PA). Patients will be encouraged to exercise based on instructions provided by the hospital staff. The patient's ability to take their radial pulse before and after PA will be assessed, and patients will be provided written instructions on the correct manner to take a radial pulse. Patients will receive daily motivational text messages from the nurse for 6 weeks. The texts will be sent via the REDCap automated system. The automated system confirms that texts were sent. The motivational interviewer nurse will confirm by phone that the patient receives her/his first text from the REDCap system.
The utility model provides a medicine belt for health, which is improved. The utility model belongs to the articles of medical care. The utility model is characterized in that a medicine bag in the medicine belt for health is composed of a heating bag, and a medicine powder bag which clings to the heating bag. Heating agent which comprises the mixture of reduced iron powders, lead powders, saw powders, cuprous oxide, and water is sealed in the heating bag. While the medicine belt for health is used, pinholes for ventilation are processed on the heating bag, the giving out heat is good for the volatilization of drugs, and the giving out heat has the function of hot compress. The powders in the medicine powder pocket which is mixed by coptis root, bornyl alcohol, etc. has a fast effect on treating diarrhea, etc. of children.
Azithromycin 2x250mg capsules to be taken orally once daily for 14 days. The first dose will be within 4 hours of randomisation. This is in addition to standard care as per local hospital advice for those patients with suspected COVID who are not admitted: i.e. symptomatic relief with rest, as-required paracetamol (where appropriate) and advice to seek further medical attention if significant worsening of breathlessness.
The use of a medical care algorithm in clinical care reduces the number of mistakes made in treating a patient. The use of a medical care algorithm in clinical care also increases the confidence of a health care provider in providing care for a patient. The invention provides a system and a method for effectively, thoroughly, and easily granting a health care provider with real-time access to critical, semi-critical, and non-critical medical care algorithms. The invention also provides a system and a method for a health care provider to consult proactive guidelines commonly used in health care. The invention also allows the health care provider a method to utilize the algorithms as a refresher tool for review and continuing education. Furthermore, the invention provides a method for the documentation of algorithm based treatments as an electronic medical record.
The present invention relates to glibenclamide solid dispersion, an oral-taking medicinal composition thereof and a preparation method thereof, which belongs to the technical field of medicine. The solid dispersion comprises the components of the following proportion: 2 to 60 wt% of glibenclamide and 98 to 40 wt% of dispersion medium. The glibenclamide in an amorphous form or a molecular form is dispersed in a noncrystalline dispersion medium, and a eutectic body is formed. The preparation method comprises a grinding method, a fusing method or a spray drying method. The glibenclamide solid dispersion prepared by the preparation method of the present invention has the advantages of nontoxic auxiliary material, no pollution, easy operation, high solubility of glibenclamide, high biological availability and good thermodynamic stability of preparations. Therefore, compared with the prior art, the present invention has the obvious substantive characteristic and the outstanding progress.
A nucleic acid transporter to deliver a nucleic acids into cells, comprising a cationic compound having a cationic head group for binding the nucleic acid and a lipid tail for association with the membrane. A cationic compound usually is a polyamine or a short basic peptide. The lipid tail is usually selected from the group consisting of plant steroid, animal steroid, isoprenoid compound, aliphatic lipid, pore forming protein, pore forming peptides and fusogenic peptides. The cationic head and the lipid tail are linked through a carbamate linkage. When polyamine is used, it is preferably either spermidine or spermine and the nucleic acid can be any of a variety, including triplex forming oligonucleotides, antisense oligonucleotide, aptamers, ribozymes, plasmids and DNA for gene therapy. Also described is a method for treating individuals using the transporter linked to a therapeutic nucleic acid.
Cardiovascular disease including valvular heart disease, contributes to an estimated 36% of all deaths over the age of 70. In particular, severe aortic stenosis is the most common valvular heart disease in the elderly in the Western world and is associated with reduced quality of life and increased mortality. TAVI has been shown to improve survival, with an all-cause mortality at 1 year similar to surgical aortic valve replacement (SAVR) with favourable outcomes long-term including improved functional capacity and quality of life. Recent evidence from randomized controlled trials suggests an increased risk of neurological events (e.g. cognitive decline) up to 1 year after TAVI in comparison to both SAVR and medical treatment. Studies have shown no change in short-term memory, working memory, verbal learning, delayed recognition and verbal fluency 3 months after TAVI. In addition, patients with severe aortic stenosis have an increased risk of mortality and future health complications. This study will be an observational, prospective cohort pilot study to examine changes in cognitive performance and functional outcomes after TAVI. We propose to recruit 34 patients for this study. Cognitive performance will be measured using a standardized cognitive battery prior to TAVI and 6 months post-TAVI. Functional capacity, changes in neuropsychiatric symptoms and quality of life will also be assessed prior to TAVI and 6 months post-TAVI. We hypothesize there will a change in cognitive performance, functional capacity, mood outcomes and quality of life over 6 months after TAVI.
OBJECTIVE: Cachexia is present in various chronic diseases and is associated with decreased quality of life and increased risk of morbidity and mortality. However, evidence regarding the association of cachexia with prognosis in patients undergoing hemodialysis is limited. We assessed cachexia using two definitions and compared prevalence, functional impairment, and prognostic impact in patients undergoing hemodialysis.
METHODS: We enrolled outpatients undergoing hemodialysis at two centers retrospectively. We assessed cachexia using the conventional cachexia (Evans' criteria) and the Asian Working Group for Cachexia (AWGC) criteria. The study examined all-cause mortality and functional status (Clinical Frailty Scale and short physical performance battery). We used Cox proportional hazards model to examine the association with prognosis, and logistic regression analysis to examine the association with functional impairment.
RESULTS: Among 367 patients (mean age, 67 years; 63 % male), cachexia prevalence, as defined by Evans' criteria and AWGC, was 21.3 % and 35.2 %, respectively. Cachexia as defined by Evans' criteria was associated with an increased risk of all-cause mortality (hazard ratio [HR], 95 % confidence interval [CI]: 1.81, 1.02-3.23). Also, cachexia as defined by AWGC criteria showed suggestive association with increasing mortality (HR, 95 % CI: 1.56, 0.90-2.70). Similar results were seen between cachexia and functional impairment.
CONCLUSIONS: Among patients on hemodialysis, cachexia was highly prevalent and was associated with poor prognosis and functional impairment. Detecting cachexia in earlier stages may be useful for risk stratification in this population.
Prior to the administration of dantrolene sodium capsules, consideration should be given to the potential response to treatment. A decrease in spasticity sufficient to allow a daily function not otherwise attainable should be the therapeutic goal of treatment with dantrolene sodium capsules. Refer to INDICATIONS AND USAGE section for description of response to be anticipated.

It is important to establish a therapeutic goal (regain and maintain a specific function such as therapeutic exercise program, utilization of braces, transfer maneuvers, etc.) before beginning dantrolene sodium capsule therapy. Dosage should be increased until the maximum performance compatible with the dysfunction due to underlying disease is achieved. No further increase in dosage is then indicated.
TMD is a common condition in the community. It may occur due to factors such as trauma, stress, occlusal disorders. Symptoms include pain, limitation in mouth opening, joint voice, postural and psychosocial disorders. TMD/RDC diagnostic criteria are used in the classification of TMD, and accordingly, it is stated that it may originate from the joint, disc and chewing muscles. In the treatment, conservative treatments such as patient education, manual therapy and exercises are applied first.

Manual therapy is an effective physiotherapy method on pain and muscle dysfunctions in musculoskeletal problems. In our study, electromyographic changes of masticatory muscles will be examined by applying manual treatment to the masticatory muscles and cervical region in myofascial TMD patients according to TMD/RC.
FIELD: medicine. ^ SUBSTANCE: invention relates to medicine, namely to otolaryngology, and deals with treatment of chronic recurring inflammatory diseases of nasal mucosa and paranasal sinuses. Method includes preliminarily obtaining of autologic lymphocytes from venous blood of patient, cultivation of obtained lymphocytes together with immunomodulator, preferably immunofan. After that from 0.1 to 3.0 ml of lymphocyte suspension, which contains 106-107 cells/ml, is introduced into paranasal sinuses with intervals between introductions from 2 to 7 days. ^ EFFECT: method is efficient, including cases of recurring polyps rhynosinutisis, allows to reduce treatment terms, increase remission terms, reduce frequency of appearance of symptoms of main and accompanying disease with reduction of need in other therapy. ^ 4 cl, 3 ex, 6 tbl
An apparatus and system for laboratory blood sample ordering, collection, and processing is described. The apparatus and system include a central computer processor, a provider user interface connected to the central computer processor, a test profile database connected to the central computer processor, and a schedule database connected to the central computer processor. An order for a blood laboratory test generates collection parameters based upon test type and the time a result is required. The system generates collection parameters, including a sample reserve fraction sufficient to provide sample for predicted future tests. Test results are communicated to the requesting provider and entered into the patient's electronic medical record. Additional sample collection is ordered if the sample reserve fraction is insufficient for subsequent requested tests.
Disclosed in the present invention is a composition using a red beet extract, which serves to protect immunomodulation and hematopoiesis from damage induced by radiation. The composition does not show any particular toxicity to splenocytes (see Fig. 1), and in in vitro and in vivo experiments, the composition is shown to promote the proliferation of splenocytes, bone marrow cells, and blood cells when the proliferation thereof is suppressed due to radiation exposure (see Fig. 2, Fig. 4 and Fig. 5). The composition also has activities such as repairing radiation-damaged DNA.
The invention relates to the field of genetic engineering, in particular to a cell membrane pore-forming protein LjGSDM and expression and application thereof. The LjGSDM gene is cloned from intestinal tissues of the Japanese lamprey, the DNA sequence of the LjGSDM gene is shown as SEQ ID NO. 2, and the amino acid sequence of the protein LjGSDM coded by the gene is shown as SEQ ID NO. 1. The protein coded by the gene LjGSDM can be recognized and combined on bacterial cell membranes, and the bacterial cells can be killed by cracking the cell membranes through pores formed by oligomerization. Meanwhile, LjGSDM can not crack cells from the outside of the cells, and the bactericidal peptide which has no toxicity to the cells of a host when being used is safe and can be used for preparing the medicine for treating infectious diseases.
PURPOSE: The increasing incidence of kidney diseases is a global concern, and current biomarkers and treatments are inadequate. Changes in renal tubule luminal volume fraction (TVF) serve as a rapid biomarker for kidney disease and improve understanding of renal (patho)physiology. This study uses the amplitude of the long T2 component as a surrogate for TVF in rats, by applying multiexponential analysis of the T2-driven signal decay to examine micromorphological changes in renal tissue.
METHODS: Simulations were conducted to identify a low mean absolute error (MAE) protocol and an accelerated protocol customized for the in vivo study of T2 mapping of the rat kidney at 9.4 T. We then validated our bi-exponential approach in a phantom mimicking the relaxation properties of renal tissue. This was followed by a proof-of-principle demonstration using in vivo data obtained during a transient increase of renal pelvis and tubular pressure.
RESULTS: Using the low MAE protocol, our approach achieved an accuracy of MAE < 1% on the mechanical phantom. The T2 mapping protocol customized for in vivo study achieved an accuracy of MAE < 3%. Transiently increasing pressure in the renal pelvis and tubules led to significant changes in TVF in renal compartments: ΔTVFcortex = 4.9%, ΔTVFouter_medulla = 4.5%, and ΔTVFinner_medulla = -14.6%.
CONCLUSION: These results demonstrate that our approach is promising for research into quantitative assessment of renal TVF in in vivo applications. Ultimately, these investigations have the potential to help reveal mechanism in acute renal injury that may lead to chronic kidney disease, which will support research into renal disorders.
OBJECTIVES: I. Evaluate the response rate of previously treated patients with recurrent non-small cell lung cancer after treatment with irinotecan and docetaxel. II. Determine the toxicity of this regimen in these patients. III. Determine the overall survival in this patient population.

OUTLINE: Patients receive irinotecan IV over 90 minutes immediately followed by docetaxel IV over 60 minutes on day 1. Treatment is repeated every 3 weeks for 6 courses in the absence of disease progression or unacceptable toxicity. Patients are followed every 3 months for 5 years or until death.
Four weeks of Vitamin D (800 IU once per day) followed by a 10 week guided resistance training (progressive strength training in a fitness center is applied; the intensity is adjusted continuously in order to obtain a sufficient training stimulus). During the training period the vitamin D intake remains. Over the whole study period participants get 400 mg calcium/day.
BACKGROUND: Heart failure (HF), a common cause of hospitalization, is associated with poor short-term clinical outcomes. Little is known about the long-term prognoses of patients with HF in Latin America.
METHODS: BREATHE was the first nationwide prospective observational study in Brazil that included patients hospitalized due to acute heart failure (HF). Patients were included during 2 time periods: February 2011-December 2012 and June 2016-July 2018 In-hospital management, 12-month clinical outcomes and adherence to evidence-based therapies were evaluated.
RESULTS: A total of 3013 patients were enrolled at 71 centers in Brazil. At hospital admission, 83.8% had clear signs of pulmonary congestion. The main cause of decompensation was poor adherence to HF medications (27.8%). Among patients with reduced ejection fraction, concomitant use of beta-blockers, renin-angiotensin-aldosterone inhibitors and spironolactone decreased from 44.5% at hospital discharge to 35.2% at 3 months. The cumulative incidence of mortality at 12 months was 27.7%, with 24.3% readmission at 90 days and 44.4% at 12 months.
CONCLUSIONS: In this large national prospective registry of patients hospitalized with acute HF, rates of mortality and readmission were higher than those reported globally. Poor adherence to evidence-based therapies was common at hospital discharge and at 12 months of follow-up.
Stepped wedge, cluster-controlled implementation science trial of 5 bundled intervention components (1. Community Health Worker, 2, Continuous Surveillance, 3. CB-Integrated Management of Newborn and Childhood Illness, 4. Group Antenatal and Postnatal Care, and 5. Balanced Post-Partum Contraceptive Counseling) implemented across 40 village clusters in Achham District, Nepal and 40 village clusters in Dolakha District, Nepal (covering a total population of approximately 300,000) in coordination with district authorities and study staff. The investigators anticipate the experimental arm will enroll approximately 12,000 women and their children over the 18mo enrollment period.
This is an open-label (both the physician and the patient know the name of the study medication), multi-center, Phase 1 study, consisting of 2 parts. The first part of the study will be non-randomized, all patients will receive the same dose. In the second part of the study, patients will be randomized (study medication assigned by chance) into 2 dose groups. The purpose of the study is to evaluate the pharmacokinetics, pharmacodynamics (clinical global impressions and formulation palatability) and safety of rabrepazole after single and multiple daily administration at 2 dose levels in children between the ages of 1 and 11 years, inclusive, with GERD. As this study is an exploratory assessment of the pharmacokinetics, pharmacodynamics and safety of rabeprazole in children, no formal hypothesis testing is applied. Safety and tolerability, including monitoring of adverse events, clinical laboratory results, physical examination, vital signs and ECG measurements, will be evaluated throughout the study. Patients will receive rabeprazole sodium as single daily oral doses for 5 successive days as a bead formulation. Patients in the first part of the study will receive single and multiple daily every 24 hours doses of 0.14 mg/kg, using increments of 1 mg dose. Safety and pk data from part 1 of the study will determine the 2 dosages to be studied in part 2 of the study.